Development and validation of blood tumor mutational burden reference standards

We announced the availability of a range of human diseased cell line based Seraseq® Blood TMB (bTMB) reference controls to support the validation and precise measurements of plasma-derived blood tumor mutational burden by targeted ccfDNA NGS assays. The poster below describes the development and validation of blood tumor mutational burden reference standards, and was presented at the 35th Meeting of the Society for Immunotherapy in Cancer (SITC 2020).